Ebola Virus: From Vaccine Technology to Pathogenesis and Outbreak Management
Vaccine Technology
Evolution of Vaccine Development: Genetic technologies have advanced, moving away from using entire weakened or killed viruses in vaccines.
mRNA Vaccines:
Contain only the messenger RNA (mRNA) coded for by the virus, not the whole virus or viral proteins.
The mRNA is injected into the host, enters host cells, and uses the host cell's machinery to produce viral proteins (e.g., proteins expressed on the surface of the viral particle).
These viral proteins are then expressed on the surface of host cells, prompting the immune system to recognize them and build antibodies.
This technology has been explored for HIV and Ebola vaccines for a while and was adapted for the COVID-19 vaccine.
Recombinant Vaccines:
An alternative to live attenuated or inactivated whole virus vaccines, especially for feared diseases like Ebola.
Involves taking another virus (e.g., a common cold virus), inserting the specific pathogen's glycoproteins (e.g., Ebola glycoproteins) into it.
The body recognizes these specific proteins on the surface of the vector virus, stimulating an immune response without exposing the individual to the full virulent pathogen.
Childhood Vaccination and Global Health Security
Gavi Alliance Focus: Organizations like Gavi (the vaccine alliance) traditionally focus on childhood vaccinations for diseases like polio, measles, and rubella, which historically caused high death rates in young children.
Motto: Their core belief is "If children survive, nations will thrive," leading to improved global health security.
Expanded Scope: In recent years, due to epidemics and pandemics (e.g., COVID-19, Ebola, influenza), their distribution efforts have expanded to include adults and older adults, not just children.
Partnerships: They collaborate with organizations like the World Health Organization (WHO) and NGOs (e.g., AIDS Foundation) to address various challenges:
Access needs: Ensuring vaccines reach populations.
Distribution: Logistic planning.
Storage: Maintaining cold chain and proper conditions (e.g., live vaccines need to be kept cold).
Tracking and Adherence: Monitoring who receives doses and ensuring multi-shot regimens are completed within required timeframes (which can be weeks to year).
Immune Response to Vaccination
Active Immune Response: Vaccines elicit an active immune response, meaning the immune system reacts similarly to a natural infection.
Innate and Adaptive Responses:
The vaccine stimulates the innate immune response, which then cascades to stimulate the adaptive immune response.
Normal Side Effects: This stimulation leads to expected bodily reactions:
Local inflammation: Redness and swelling at the injection site as the innate response is activated.
Fever: Release of cytokines stimulates a fever, indicating an adaptive immune response.
Misconceptions: A low-grade fever or localized inflammation post-vaccine is a sign the immune system is responding, not that the vaccine is causing illness.
Recombinant Vaccine Safety: For recombinant vaccines, it is impossible to contract the disease being vaccinated against because the whole virus is not present in the vaccine.
Ebola Virus: Biology and Outbreaks
Current Ebola Outbreak (September 2023)
Location: Democratic Republic of Congo (DRC), specifically the Hassai province (rural, limited health resources).
Cases and Deaths: Approximately confirmed or probable cases, with deaths, indicating a case fatality rate over .
Patients are presenting in advanced stages of illness, making treatment difficult and suggesting more undetected cases.
Strain: The Zaire strain, for which a vaccine exists.
Response: The WHO has requested $21 million in aid and vaccine doses from member states. The vaccine is produced by a pharmaceutical company in New Jersey, USA. ~ doses have been rolled out, but this may be insufficient given unknown exposure levels.
Evolving Situation: The duration and spread of the outbreak are uncertain.
Ebola Virus Strains
There are six strains of Ebola virus.
Zaire Strain: Historically responsible for the majority of human outbreaks; the current vaccine targets this strain. Renaming has caused some confusion; sometimes referred to simply as "Ebola."
Sudan Strain: Responsible for some outbreaks, notably recent ones in Uganda, for which a vaccine was not initially available.
Reston Strain (Non-Human Pathogenic):
Discovered in Reston, Virginia, USA, in primates imported from the Philippines for research.
Monkeys showed signs of illness, and while human workers were exposed, none became sick.
Humans exposed carried antibodies, indicating infection without disease.
Unique Transmission: This strain was believed to be aerosolized, unlike other strains known primarily for transmission via bodily fluids, challenging existing knowledge of Ebola transmission.
Implications: Demonstrated that not all Ebola strains cause human disease or transmit in the same manner, but mutation could change this.
Reservoir and Transmission
Reservoir: Fruit bats (bushmeat consumption is a known spillover event).
Animal-to-Human Transmission: Primarily through consumption of infected animal meat (e.g., bushmeat).
Human-to-Human Transmission: Through direct contact with bodily fluids (saliva, blood, urine, feces, vomit) from an infected person or contaminated items.
Contaminated Articles: Fluids can contaminate clothing, bedding, and medical equipment. The virus can survive outside the body for some time, posing a risk through contact with contaminated surfaces.
Sexual Transmission: Individuals who have recovered from Ebola can harbor the virus in semen and transmit it sexually to partners. This was a significant discovery made as survivorship improved, allowing for studies of survivors.
Symptomatic Transmission: With the exception of sexual transmission via semen (which can occur after recovery), person-to-person transmission occurs after symptoms begin.
Early symptoms (fever, aches) are non-specific, meaning individuals may transmit the virus before realizing they have Ebola.
Close Contact: Transmission is typically associated with close contact (within feet) due to fluid exposure. Viral survival is several hours on dry surfaces or in bodily fluids at room temperature.
Dead-end Host: Humans are considered a dead-end host for Ebola; there is no evidence of human-to-animal transmission.
Incubation Period and Symptoms
Incubation Period: to days (guiding the -week quarantine recommendation for exposed individuals).
Symptoms: Occur in two phases:
"Dry" Symptoms (Early): Tiredness, body aches, low-grade fever, headaches. A rash may develop in some people by days .
"Wet" Symptoms (Later): Severe vomiting, diarrhea, and eventually hemorrhage (bleeding).
Ebola Outbreak History and Lessons Learned
1976 (Zaire/DRC & South Sudan): First recognized outbreaks. Tracked to hospital practices involving syringe reuse, leading to rapid spread. Identified distinct Zaire and Sudan strains.
1994 (Cote D'Ivoire): Demonstrated the effectiveness of personal protective equipment (PPE) in reducing transmission among healthcare workers.
1995 (Zaire): Marked the first significant international response to an Ebola outbreak, overcoming initial fears of sending aid workers into deadly outbreaks.
2014-2016 (West Africa - Liberia, Guinea, Sierra Leone):
Highly effective PPE protocols reduced healthcare worker infections to about .
Most transmission occurred within families.
Quarantine Failure: A severe error was made in Monrovia, Liberia, where authorities forcibly walled off a slum area overnight, leading to public anger and non-compliance, becoming a case study in how not to implement quarantine.
2018-2020 (DRC & Uganda):
Approximately two-thirds () of infected individuals died.
First Vaccine Use: This was the first time an Ebola vaccine (targeting the Zaire strain) was used. Initially under "compassionate use" status (clinical data showed efficacy, but no full regulatory approval).
Vaccine Production: Merck manufactured the vaccine, with mass production occurring in Hannover, Germany.
Ethical Challenges: Limited vaccine supply led to difficult ethical questions regarding prioritization and distribution.
Post-2020 Small Outbreaks (DRC): Led to investigations on whether these were new outbreaks or continuations of previous ones.
Investigation Methods: Genetic sequencing of viral strains, epidemiological surveillance (travel history, contacts), and source tracing (e.g., whether from different bat populations).
These methods revealed some outbreaks were linked across miles, implying undetected cases or unknown transmission routes, while others were new spillover events.
Recent Uganda Outbreaks (Sudan Strain):
Unique because the Zaire strain vaccine was ineffective against the Sudan strain.
Response relied on basic prevention (PPE, quarantine).
New Vaccine Pilot: A new vaccine for the Sudan strain was piloted in a clinical trial during these outbreaks, credited with containing them within about months.
Ebola Pathogenesis: How the Virus Causes Disease
Initial Infection: Ebola virus enters the body and is engulfed by macrophages and dendritic cells (antigen-presenting cells).
Immune System Overwhelm (Lymphatic System):
Infected macrophages and dendritic cells migrate to the liver, spleen, blood, and particularly the lymph nodes.
Viral replication occurs rapidly within lymph nodes.
Crucially, uninfected lymphocytes (T cells, B cells, natural killer cells) within the lymphatics start to die off or fail to reproduce; the exact mechanism is unclear, but lymph nodes seem overwhelmed.
This leads to a depletion of essential immune cells, severely compromising the host's immune response.
Vascular System Damage:
Ebola uses a glycoprotein on its surface to bind to endothelial cells lining blood vessels.
The virus disseminates throughout the body.
Infection of endothelial cells leads to their damage.
Pro-inflammatory Response (Cytokine Storm):
Infected macrophages and dendritic cells present antigens, stimulating the innate immune system.
This leads to a robust release of pro-inflammatory cytokines, causing initial symptoms like fever, fatigue, and sometimes a rash.
Disruption of Coagulation (The Bleeding Puzzle):
Initial Hypercoagulation: Infected macrophages release "tissue factor," which stimulates the extrinsic coagulation pathway.
This pathway rapidly produces thrombin, which then generates fibrin, leading to widespread microclot formation in tissues (e.g., lungs, kidneys).
The process also involves decreased anticoagulant effects, further promoting clotting.
Subsequent Hypocoagulation and Hemorrhage: These microclots consume the body's clotting factors.
By the time symptoms progress to severe bleeding, the body has no clotting factors left to stop it.
This complex interplay of initial widespread clotting leading to later widespread bleeding is a hallmark of Ebola.
Adrenal Gland Impact and Shock:
Ebola infects the adrenal glands.
This infection reduces the production of cortisol and catecholamines (stress hormones).
The lack of these hormones leads to severe hypotension (low blood pressure).
To compensate, cells lose sodium, worsening the condition.
Uncontrolled hypotension leads to hypovolemic shock, as blood cannot be effectively pumped to vital organs like the brain.
Blood Vessel Permeability:
Ebola infection and the associated immune response (e.g., nitric oxide release) cause endothelial cells to stretch and become permeable (or "leaky").
This allows blood to leak out of vessels, contributing to internal and external bleeding.
Combined Effect: The combination of severe bleeding (due to consumed clotting factors and leaky vessels) and profound low blood pressure (due to adrenal damage), compounded by immune suppression, leads to multi-organ failure and death if untreated.
Treatment and Outcomes
Supportive Therapy (Primary Treatment):
The first and most crucial line of defense.
Aims to stabilize the patient: IV fluids to combat fluid loss and dehydration (from vomiting/diarrhea), fever reducers, blood pressure support.
Has significantly reduced the case fatality rate from approximately to about .
Allows the body to stabilize and potentially fight off the virus.
Immune Therapy: Can be added after the patient is stabilized, further improving chances of survival.
Antivirals: Less effective due to the virus's rapid replication rate and the complex, multi-systemic damage it causes.
Challenges in Drug Development: Developing drugs to target specific pathways disrupted by Ebola (e.g., coagulation, vascular integrity) is difficult because the virus affects so many interlocking systems.
Survivor Status:
Survivors typically carry antibodies against Ebola for years or more, providing protection against subsequent infection by the same strain.
Role in Response: Historically, survivors have been utilized in caretaking roles (e.g., for children of infected families) because they possess immunity and reduce community fear.
Long-term Consequences: Many survivors experience chronic health issues, including chronic gastrointestinal pain, generalized aches, persistent fatigue, and problems with vision and hearing.
Fear and Stigmatization: Ebola outbreaks are often accompanied by intense fear, leading to stigmatization, ostracism, and even violence (e.g., burning of houses or clinics) against affected individuals or response efforts.